Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14216819 | 0.92 | MTNR1A (0.53) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL14217391 | 0.81 | MAPT (0.45) | HSD17B2HSD17B1UTS2RMEN1KMT2A | |
| SCHEMBL14216987 | 0.73 | HTR2A (0.44) | UTS2RMEN1KMT2A | |
| SCHEMBL20264517 | 0.71 | HSD17B2 (0.61) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL8179559 | 0.71 | HSD17B2 (0.55) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL14216818 | 0.69 | HTR2A (0.47) | MTNR1AMTNR1BUTS2R | |
| SCHEMBL11027897 | 0.68 | HSD17B2 (0.61) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL28392555 | 0.68 | HSD17B2 (0.55) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL20278104 | 0.68 | MTNR1A (0.57) | MTNR1AMTNR1BHSD17B2HSD17B1 | |
| SCHEMBL11410256 | 0.68 | HSD17B2 (0.57) | MTNR1AMTNR1BHSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | MTNR1A 1639/4885MTNR1B 1037/4885HSD17B2 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.